MYASTHENIA GRAVIS, GENERALIZED
Clinical trials for MYASTHENIA GRAVIS, GENERALIZED explained in plain language.
Never miss a new study
Get alerted when new MYASTHENIA GRAVIS, GENERALIZED trials appear
Sign up with your email to follow new studies for MYASTHENIA GRAVIS, GENERALIZED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug DNTH103 aims to tame muscle weakness in myasthenia gravis
Disease control OngoingThis Phase 2 study tests a drug called DNTH103 (claseprubart) in 65 adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either the drug or a placebo, first through an IV and then as injections under the skin every two weeks for…
Matched conditions: MYASTHENIA GRAVIS, GENERALIZED
Phase: PHASE2 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Engineered immune cells take on rare Muscle-Weakening disease
Disease control OngoingThis early-phase study tests a new treatment called SENL103 for people with refractory generalized myasthenia gravis, a condition that causes severe muscle weakness. The treatment uses the patient's own immune cells, modified to target and destroy harmful cells that attack the mu…
Matched conditions: MYASTHENIA GRAVIS, GENERALIZED
Phase: PHASE1 • Sponsor: Ting Chang, MD • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Hope for rare Muscle-Weakening disease: new drug trial targets Antibody-Negative patients
Disease control OngoingThis study tests an investigational drug called efgartigimod, given intravenously, for adults with generalized myasthenia gravis (gMG) who do not have the typical acetylcholine receptor antibodies. The trial compares the drug to a placebo to see if it improves daily activities an…
Matched conditions: MYASTHENIA GRAVIS, GENERALIZED
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC